Sen. Grassley urges FDA to implement recommendations of Inspector General for human subjects in clinical trials
WASHINGTON — Sen. Chuck Grassley is calling on the Food and Drug Administration to implement recommendations stemming from an independent review of the agency’s oversight of clinical trials involving human subjects.
“We’re all in debt to the individuals who volunteer for the clinical trials that advance medicine and lead to lifesaving cures. The Food and Drug Administration needs to make sure these human subjects are treated properly and fully informed,” Grassley said.
Grassley made his appeal in a letter to the FDA Commissioner. The text is below. The report of the Inspector General for the Department of Health and Human Services containing the recommendations is posted at http://finance.senate.gov, along with this news release.
Next Article Previous Article
- Wyden Statement on the National Taxpayer Advocate Appointment
- Wyden Statement on the Senate Floor on Protecting Women’s Health Care
- Wyden Statement on GAO Report on Implementation of Republican Tax Cuts
- Wyden Statement at Finance Committee Hearing on the Trump Administration’s FY 2021 Budget with HHS Secretary Alex Azar
- Finance Democrats Denounce Trump Admin For Harmful Medicaid Block Grant Proposals